Khaberni - The market value of the American company Eli Lilly exceeded a trillion dollars on Friday, making it the first pharmaceutical company to enter the club of trillion-dollar companies, a sector dominated by technology companies. This achievement reflects the company's rising stature in the obesity treatment and weight loss market.
The company's shares have increased by more than 35% since the start of the year, driven by increasing demand for obesity drugs, which over the past two years have become one of the most profitable healthcare sectors with the introduction of new highly effective drugs.
Although Novo Nordisk was a leader in this market, the popularity of the drugs "Mongaru" and "Zibaund" produced by "Eli Lilly" has steadily increased, boosting its share in medical prescriptions at the expense of competing companies.
Eli Lilly's stock reached a record high during trading, rising by 1% in the latest session to reach 1,051 dollars, making the company the highest valued among major pharmaceutical companies.
According to data from the London Stock Exchange group, the company's valuation is about 50 times its expected earnings over the next 12 months, reflecting investors' confidence in the continued growth of the obesity drug market.
The performance of the company's stock has significantly outperformed the American stock market; since the launch of "Zibaund" in late 2023, Eli Lilly's stock has risen by more than 75%, compared to a rise in the "Standard & Poor's 500" index which did not exceed 50% during the same period.
In its latest quarterly results, the company announced revenues that exceeded 10.09 billion dollars from its portfolio of obesity and diabetes drugs, which is more than half of its total revenue of 17.6 billion dollars.
